Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cabozantinib + Carfilzomib + Dexamethasone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cabozantinib | Cometriq | Cabometyx|Cabozantinib-s-malate|XL184 | AXL Inhibitor 29 FLT3 Inhibitor 61 KIT Inhibitor 55 MET Inhibitor 56 RET Inhibitor 48 ROS1 Inhibitor 19 VEGFR2 Inhibitor 36 | Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov). |
Carfilzomib | Kyprolis | PR-171 | Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). | |
Dexamethasone | Adexone | Desametasone |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03201250 | Phase Ib/II | Cabozantinib + Carfilzomib + Dexamethasone | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | Terminated | USA | 0 |